Navigation Links
Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
Date:2/1/2010

an AV fistula or AV graft for hemodialysis. Results showed that Vascugel was well tolerated, with no difference in early complication rates between the Vascugel and placebo groups at four weeks (10.9 percent vs. 21.1 percent, respectively). Results also demonstrated a trend for improved primary patency at 24 weeks in patients treated with Vascugel compared to placebo.

Building on the successful results to date for Vascugel, Pervasis continues to apply its proprietary endothelial technology platform to develop additional therapies to treat vascular disease. Data for PVS-10200, a preclinical compound being developed to treat interventions performed for peripheral arterial disease (PAD), were published in the December issue of the Journal of Vascular and Interventional Radiology (Nugent et al. J Vasc Interv Radiol 2009; 20(12):1617-1624). In a preclinical model of PAD, administration of PVS-10200 at the time of angioplasty and stent placement enhanced blood vessel healing compared to angioplasty and stenting alone. Pervasis is now preparing to begin a Phase 1/2 study of PVS-10200 in the first half of 2010.

About Pervasis

Pervasis Therapeutics, Inc. is a clinical stage company developing a broad portfolio of biologically active therapeutics. Building on its deep understanding of the specialized role that the endothelium plays in regulating natural healing and repair processes associated with disease, Pervasis is advancing groundbreaking new therapies to dramatically improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts -- the failure of which result in serious complications and a significant increase in medical costs. The company's most advanced program, Vascugel®, has demonstrated proof of concept and safety in two Phase 2 trials in patients undergoing arteriovenous access procedures for hemodialysis. Pervas
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013 3SBio Inc. (NASDAQ: ... China -based biotechnology company focused ... announced today that, at an extraordinary general meeting ... in favor of the proposal to authorize and ... merger dated February 8, 2013, among Decade Sunshine ...
(Date:5/23/2013)... PARÍS, 24 de mayo de 2013  Volcano ... desarrollador y fabricante de herramientas de precisión para ... tratamiento de la enfermedad vascular periférica y coronaria, ... ( Ad enosine V asodilator I ... durante la sesión de ensayo clínico hot line ...
(Date:5/23/2013)... -- Amgen (NASDAQ: AMGN ) will present at ... Thursday, May 30, 2013, at the Westin Boston Waterfront Hotel, ... Daylight Time. Arvind Sood , vice president ... Live audio of the presentation can be accessed from the ... A replay of the webcast will also be available on ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... Hospital (MGH) Cancer Center has purchased four radiation therapy treatment ... and one Elekta Synergy® S. The order, which includes ... facility to offer patients a complete cancer treatment solution from ... systems position MGH to take advantage of Volumetric ...
... 2 The Asthma and Allergy Foundation of America (AAFA) ... annual research project ranks the fall,s 100 most challenging cities ... this year are: McAllen, TX (1); Wichita, KS (2); Louisville, ... In addition, according to a recent AAFA survey, fall ...
Cached Medicine Technology:Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution 2New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 2New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 3New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 4New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 5New Fall Allergy Capitals(TM) Reveal the Most Challenging Cities for Allergy Sufferers 6
(Date:5/25/2013)... An experienced Chandler dentist has just ... JD Media Surge, LLC. , http://www.ChandlerDentalExcellence.com/Teeth-Whitening.php ... depending on the treatment, can be performed in the ... best method will be chosen for the individual patient. ... A special peroxide-based whitening gel is used along with ...
(Date:5/25/2013)... Actos lawsuit claims pending ... Court, Western District of Louisiana, continue to move forward, ... Management Order issued on May 21st, the Court has ... in the Actos bladder cancer litigation, as well as ... Liability Litigation, MDL No. 2299) , “We continue to ...
(Date:5/25/2013)... 25, 2013 Radius Engineering International ... company in the US and has been building ... over 35 years. M.E. and President, Walton McCarthy, ... NBC Weapon Fundamentals and Shelter Engineering Standards, Sixth ... on shelter engineering. McCarthy is considered the leading ...
(Date:5/25/2013)... NY (PRWEB) May 25, 2013 On May ... many people do not wish to discuss or plan for ... life. FuneralFinancials.com released a Must-Do List to ... 1. Funeral Financials recommends, “Creating a personal fact sheet.” , ... to organize financial information and personal data. It may ...
(Date:5/25/2013)... 2013 On May 25, Voices Against ... and advocacy, comments on a new study by the ... cold atmospheric plasma into brain cancer treatment may help ... a Science Daily article, physicists from the ... physicians demonstrated the “synergistic effect of cold atmospheric plasma ...
Breaking Medicine News(10 mins):Health News:Chandler Dentist Launches Teeth Whitening Service Page on Website in Partnership with JD Media Surge, LLC 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2
... take on pilots, health,workplace injuries connected to chronic ... be presented at Preventive Medicine 2008,the American College ... Austin, Texas., Long-Haul Flights May be Hazardous ... acute stress phenomena associated with,frequent take offs and ...
... together to provide dental offices with exposure, to the ... and other Sikka Software products that assist, dentists and their ... performance of their practice. Dental Economics will utilize,Sikka Software,s trending, ... ...
... transaction will be hosted at 11:30 am Eastern ... on ... Inc. ("Meadowbrook") (NYSE: MIG ) and ProCentury,Corporation ("ProCentury") (Nasdaq: ... a transaction valued at,approximately $272.6 million in cash and stock to ...
... Feb. 20 According to Anapol ... http://www.anapolschwartz.com/attorneys/jim_ronca.shtml ), a New England,Journal of ... in the February 21, 2008, print ... Trasylol(R), used in coronary artery bypass ...
... Dana-Farber Cancer Institute have found a previously unknown molecular ... blood vessels when body parts are jeopardized by poor ... understanding of blood vessel formation. In the future, though, ... could be manipulated as a means of treating heart ...
... / ST. PAUL (February 20, 2008) Understanding the ... help in the battle against AIDS, and University of ... direction., Hiroshi Matsuo, Ph.D., and Reuben Harris, Ph.D., co-investigators ... of Biochemistry, Molecular Biology and Biophysics at the University ...
Cached Medicine News:Health News:News Briefs from Preventive Medicine 2008 2Health News:News Briefs from Preventive Medicine 2008 3Health News:Sikka Software and Dental Economics Announce Alliance 2Health News:Meadowbrook Insurance Group, Inc. and ProCentury Corporation Reach Agreement to Merge in $272.6 Million Transaction 2Health News:Meadowbrook Insurance Group, Inc. and ProCentury Corporation Reach Agreement to Merge in $272.6 Million Transaction 3Health News:Meadowbrook Insurance Group, Inc. and ProCentury Corporation Reach Agreement to Merge in $272.6 Million Transaction 4Health News:Meadowbrook Insurance Group, Inc. and ProCentury Corporation Reach Agreement to Merge in $272.6 Million Transaction 5Health News:Meadowbrook Insurance Group, Inc. and ProCentury Corporation Reach Agreement to Merge in $272.6 Million Transaction 6Health News:Meadowbrook Insurance Group, Inc. and ProCentury Corporation Reach Agreement to Merge in $272.6 Million Transaction 7Health News:Anapol Schwartz Attorney Representing Trasylol(R) Victims Says Medical Study - Confirming Heart Bypass Drug Mortality Risk - to Open Floodgates for More Litigation 2Health News:Another way to grow blood vessels 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: